ArticleFrontiers in aging neuroscience2025
Predictive value of pan-immune-inflammation value in the prognosis of adults with status epilepticus: a retrospective study.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive capacity of the pan-immune-inflammation value (PIV) for functional outcomes in patients with status epilepticus (SE). Methods: In this study, we investigated and confirmed the prognostic significance of PIV in adult patients with SE. Clinical information and laboratory test data of the patients were extracted. We gathered the information on 30-day mortality following SE and used the modified Rankin scale (mRS) to assess functional prognosis. Multivariable logistic regression models were employed to assess the relationship between PIV and SE prognosis. Additionally, receiver operating characteristic (ROC) curve analysis was conducted to identify the optimal PIV threshold for predicting poor outcomes of SE patients. Results: Initially, the discovery cohort comprising 132 SE patients were examined. The findings revealed that 18.2% (24/132) of patients died within a 30-day period post-SE, and 25.8% (23/89) experienced unfavorable prognosis during the 6-month follow-up period. Multivariate logistic regression analysis showed that higher PIV on admission was independently related to poor 6-month prognosis of SE patients (odds ratio: 1.002; 95% confidence interval, 1.000-1.004; Conclusion: Higher PIV is strongly correlated with an elevated risk of unfavorable SE prognosis. Our results suggest that PIV is a simple and reliable predictor for SE prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.